Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620022 · ClinicalTrials.gov registry record · Phase 3
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00620022 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 90 participants.
The verdict
NCT00620022, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study compared the effect of indacaterol (300 μg once daily \[od\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
Interventions
- DRUG Placebo
- DRUG Indacaterol 300 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620022
The ClinicalTrials.gov registry entry for NCT00620022 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00620022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620022 about?
NCT00620022 is a clinical study titled "The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". This study compared the effect of indacaterol (300 μg once daily \[od\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
What is the current status of trial NCT00620022?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2008-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00620022?
The interventions under investigation include: Placebo (DRUG), Indacaterol 300 μg (DRUG).
Who is sponsoring clinical trial NCT00620022?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.